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ctivation of the serine/threonine kinase Akt/PKB
positively impacts on three cellular processes relevant
to tumor progression: proliferation, survival, and
cell size/growth. Using a three-dimensional culture model
of MCF-10A mammary cells, we have examined how Akt
influences the morphogenesis of polarized epithelial
structures. Activation of a conditionally active variant of Akt
elicits large, misshapen structures, which primarily arise
from the combined effects of Akt on proliferation and cell
size. Importantly, Akt activation amplifies proliferation during
the early stages of morphogenesis, but cannot overcome
A
 
signals suppressing proliferation in late-stage cultures. Akt
also cooperates with oncoproteins such as cyclin D1 or
HPV E7 to promote proliferation and morphogenesis in
the absence of growth factors. Pharmacological inhibition
of the Akt effector, mammalian target of rapamycin (mTOR),
with rapamycin prevents the morphological disruption
elicited by Akt activation, including its effect on cell size
and number, and the cooperative effect of Akt on onco-
gene-driven proliferation, indicating that mTOR function
is required for the multiple biological effects of Akt activa-
tion during morphogenesis.
 
Introduction
 
The individual structural units (called acini in the mammary
gland) comprising glandular epithelium display remarkable
homogeneity in terms of their polarized hollow architecture
and uniform size, which critically depends on how epithelial
cells interact with each other, with surrounding cells in their
microenvironment, as well as with hormones, growth factors,
and other cues provided by the extracellular matrix (Bissell
and Radisky, 2001). Like all tissue homeostasis, maintenance
of these structures requires the tight regulation of growth
(cell size), proliferation (cell number), and survival at the
level of individual cells (Conlon and Raff, 1999). Disruptions
in cell growth, proliferation, and survival are all recognized
as key features of oncogenic transformation; however, little
is understood about how perturbations of these basic processes
within individual epithelial cells ultimately impact on the
higher order architecture of a glandular unit (Hanahan and
Weinberg, 2000; Bissell and Radisky, 2001).
The culture of epithelial cells on three-dimensional (3D)
basement membrane gels promotes their organization into
spheroid-shaped structures that share properties with glandular
epithelium in vivo; hence, such cultures can be used to address
fundamental questions about processes that disrupt epithelial
architecture (Streuli et al., 1991; Petersen et al., 1992;
O’Brien et al., 2002). For example, we recently found that
the induction of constitutive proliferation or inhibition of
apoptosis was insufficient to prevent lumen formation during
the morphogenesis of mammary acini; rather, the combined
disruption of these two processes was required to fill the
lumen (Debnath et al., 2002).
While investigating the processes that contribute to lumen
formation in mammary acini, we found that matrix-attached
cells occupying the periphery of developing acini could be
distinguished from centrally localized cells by several criteria.
The outer cells display apical–basal polarity and deposit
basement membrane components (laminin 5 and collagen
IV) on their basal surface, whereas the centrally localized
cells do not. Interestingly, we also observed a dichotomy in
activation of the serine/threonine kinase Akt/PKB, which
was present in a stochastic pattern exclusively in the outer,
matrix-attached cells, but not in the centrally located cells that
subsequently underwent apoptosis during lumen formation
(Debnath et al., 2002). This distinct pattern during acinar
development led us to consider whether increased activation
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of Akt could promote the survival of cells occupying the lumi-
nal space. Akt can regulate cell survival by phosphorylating
multiple proteins, including the proapoptotic protein BAD
and the Forkhead family of transcription factors (Datta et al.,
1997; Brunet et al., 2001). Notably, the PI3K/Akt pathway is
activated in a wide spectrum of cancers, due to activation of
an upstream growth factor receptor pathway and/or to loss of
function of the negative regulatory phosphatase and tumor
suppressor protein PTEN (Cantley and Neel, 1999; Vivanco
and Sawyers, 2002). Moreover, the increased expression of
activated Akt in the mouse mammary gland or brain cooper-
ates with other oncogenic insults to promote tumor forma-
tion, presumably due to its ability to increase cell survival
(Holland et al., 2000; Hutchinson et al., 2001).
Although the PI3K/Akt pathway is best recognized as a
regulator of mammalian cell survival, recent studies have
indicated that this pathway controls other critical cellular
functions, including proliferation, growth, and metabo-
lism. Notably, Akt can positively impact cell proliferation
through numerous signals to the cell cycle machinery and
increase cell growth and size by activation of the mam-
malian target of rapamycin (mTOR) pathway (Lawlor
and Alessi, 2001; Abraham, 2002; McManus and Alessi,
2002). How each of these processes actually contributes to
the phenotype mediated by PI3K/Akt activation in cancers
is an issue of fundamental importance. Moreover, the ef-
fects of Akt activation on the formation and maintenance
of glandular epithelial structures has not previously been
reported, and it remains unclear if specific Akt-regulated
processes or pathways are necessary for its phenotypic ef-
fects on epithelial architecture. As the PI3K/Akt pathway
is often activated in epithelial cancers, this information
may be useful in the therapy of carcinomas (Vivanco and
Sawyers, 2002).
In this study, we sought to better understand how activa-
tion of the PI3K/Akt pathway affects the morphogenesis of
epithelial structures by expressing an inducible, activated
variant of Akt1 within MCF-10A mammary acini. Akt acti-
vation elicits large, misshapen structures, which result from
enhanced proliferation and increased cell size, along with
variability in size and shape displayed by individual cells
within these structures. Remarkably, Akt activation also am-
plifies the proliferation induced by cyclin D1 or HPV E7
during morphogenesis and cooperates with these oncopro-
teins to promote proliferation and morphogenesis in the ab-
sence of growth factors. Finally, we demonstrate that the
effects of Akt activation on morphological disruption, indi-
vidual cell size and shape, as well as oncogene-driven prolif-
eration are all prevented by rapamycin, a highly specific
pharmacological inhibitor of the Akt effector mTOR, sug-
gesting that mTOR is functionally required for all of the
phenotype changes elicited by Akt during the morphogene-
sis of mammary epithelial structures.
 
Results
 
Akt activation within mammary acini elicits 
morphological disruption
 
To study the effects of Akt activation on acinar morphogen-
esis, we expressed a conditionally activated variant of Akt in
MCF-10A mammary epithelial cells. This previously de-
scribed version of Akt (hereafter called ER-Akt) consists of a
fusion of the Akt1 kinase domain, containing the 
 
src
 
 myris-
toylation sequence at its NH
 
2
 
 terminus, to the hormone
binding domain of a mutant estrogen receptor (ER) specifi-
cally responsive to the estrogen analogue 4-hydroxytamox-
ifen (OHT) (Kohn et al., 1998). Stable pools of MCF-10A
cells expressing ER-Akt were established by retroviral infec-
tion. Treatment of these cells (cultured as monolayers) with
OHT led to the activation of the Akt chimeric protein,
as demonstrated by immunoblotting with antibodies di-
rected against activation-specific phosphorylation sites in Akt
(Ser
 
473
 
 and Thr
 
308
 
) (Fig. S1, A and B, available at http://
www.jcb.org/cgi/content/full/jcb.200304159/DC1); maxi-
mal phosphorylation was obtained with 100–1000 nM
OHT. OHT treatment increased phosphorylation of sev-
eral known Akt substrates, including Forkhead ligand
1 (FKHR-L1), tuberin (tuberous sclerosis complex 2
[TSC2]), and glycogen synthase kinase 3 (Fig. S1 C) (Datta
et al., 1999; Manning et al., 2002). Activation of the ER-
Akt chimera by OHT and the resulting phosphorylation of
Akt substrates was significantly inhibited by the PI3K inhib-
itor LY294002, confirming previous reports that this condi-
tionally active version of Akt is still subject to regulation by
PI3K despite the absence of the PIP3-binding pleckstrin ho-
mology domain (Fig. S1, B and C) (Kohn et al., 1998). Fi-
nally, OHT treatment of ER-Akt–expressing cells led to in-
creased surface expression of GLUT1, a glucose transporter
regulated by Akt activation (Fig. S1 D) (Plas et al., 2001;
Edinger and Thompson, 2002). Overall, these results dem-
onstrate that activation of ER-Akt in MCF-10A cells in-
duces multiple responses previously shown to be associated
with Akt activation.
ER-Akt–expressing MCF-10A cells were cultured on a re-
constituted basement membrane gel derived from Engel-
breth-Holm-Swarm tumor (EHS; Matrigel™) and treated
with either 1 
 

 
M OHT or ethanol control (EtOH) starting
on day 2 or 3 in 3D culture; cultures were thereafter refed
every 4 d. The activation of Akt during morphogenesis led
to large, misshapen structures with cells occupying the lumi-
nal space (Fig. 1 A, right and center columns). Immuno-
staining with an antibody that detects phosphorylated Ser
 
473
 
in Akt (
 

 
P-Akt Ser
 
473
 
) revealed that high levels of activated
Akt were present throughout these structures both in cells
with direct matrix contact and in those occupying the lumi-
nal space; in contrast, control acini exhibited a stochastic
pattern of Akt activation confined to cells in the periphery
and similar to that observed in uninfected MCF-10A acini
(Debnath et al., 2002).
Individual activated Akt structures displayed varying de-
grees of morphological disruption and changes in overall
structure size. The average diameter of structures from
OHT-treated cultures was 112.7 
 
 
 
33.2 
 

 
m (mean 
 

 
SD) versus 61.9 
 

 
 16.3 
 

 
m in controls (P 
 
 
 
0.001 by 
 
t
 
test). Evidence of larger size and morphological disruption
was evident as early as day 8 in 3D culture and progres-
sively increased thereafter; nevertheless, acini expressing ac-
tivated ER-Akt did not invade the matrix and continued to
secrete the basement membrane protein laminin 5 during
morphogenesis (Fig. 1 B).
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Akt activation does not completely prevent luminal 
apoptosis during morphogenesis
 
We then investigated whether Akt activation affected the in-
duction of apoptosis in the luminal space of mammary struc-
tures during morphogenesis by immunostaining with an anti-
body against the cleaved, activated form of caspase-3 (
 

 
-active
caspase-3). Surprisingly, we were able to detect significant
caspase-3 activation in structures where Akt was activated. As
in control acini, the apoptotic cells were confined to those
that lacked direct contact with matrix and occupied the lumi-
nal space (Fig. 1 B, top). OHT treatment of both wild-type
MCF-10A acini and structures only expressing the hormone
binding domain of ER did not lead to increased luminal
apoptosis, indicating that OHT did not nonspecifically in-
duce apoptosis in the absence of ER-Akt (unpublished data).
Previously, we had shown that lumen formation in MCF-
10A acini involved the selective death of centrally located
cells during days 8–12 of morphogenesis; thereafter, apopto-
sis continued to eliminate residual proliferating cells and
maintain the hollow lumen (Debnath et al., 2002). Because
we observed large numbers of both viable and dying cells in
the lumens of active Akt structures throughout morphogen-
esis, we more closely examined luminal apoptosis in control,
active Akt, and Bcl-2-expressing structures at various time
points. Indeed, the lumens of active Akt structures con-
tained fewer activated caspase-3–positive cells compared
with controls; nevertheless, the protection from apoptosis
provided by active Akt was significantly weaker than Bcl-2
(Fig. 1 C, left). Overall, these results indicate that Akt acti-
vation can provide partial protection from luminal apoptosis
during acinar morphogenesis. Remarkably, both during and
after lumen formation, greater numbers of viable cells were
observed in the lumen of active Akt structures compared
with both control and Bcl-2–expressing structures; in late-
stage (day 20) structures, the active Akt structures continued
to possess living cells in their luminal spaces, whereas the lu-
Figure 1. Effects of Akt activation on mammary acinar morphogenesis and luminal apoptosis. (A) MCF10A cells expressing ER-Akt were 
cultured on Matrigel for 15–16 d in the presence of ethanol as vehicle control (top) or 1 M OHT (bottom). Shown are representative phase 
images (left), confocal cross sections through the middle of DAPI-stained structures (center), and equatorial DAPI-stained confocal cross 
sections of structures immunostained with -phospho Akt Ser473 (green, right). Bars, 25 m. (B) ER-Akt structures grown in 3D with or without 
1 M OHT for the indicated times were immunostained with -activated caspase 3 (green) and -laminin 5 (red) and counterstained with 
DAPI (blue). Shown are equatorial confocal cross sections. Bars, 25 m. (C) Structures of the indicated cell types were fixed and immunostained 
as illustrated in B. For both graphs, cells occupying the lumen were defined as those lacking direct contact with basement membrane as 
delineated by -laminin 5 staining. (C, left) The percent of cells positive for activated caspase-3 observed in the lumen at various times was 
quantified; each time point represents the mean  SD of 90 structures obtained from three independent experiments. (C, right) The mean  SEM 
number of viable cells, defined as cells negative for activated caspase-3 present in the lumens of individual structures was enumerated; each 
time point represents 90 structures obtained from three independent experiments. (D) ER-Akt cells were cultured on EHS for 6 d in the presence 
of ethanol control (top) or 1 M OHT and immunostained with -P-Akt Ser473 (green, top) or -P-FKHR/FKHR-L1 (green, bottom). Shown are 
equatorial cross sections counterstained with DAPI (blue). Bars, 25 m.
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mens of both control and Bcl-2–expressing acini were hol-
low (Fig. 1 C, right). Finally, we examined the spatial phos-
phorylation pattern of the Forkhead transcription factors,
whose phosphorylation-mediated inactivation is a key medi-
ator of cell survival by Akt (Brunet et al., 2001). 
 

 
-Phos-
pho-FKHR/FKHR-L1 immunostaining confirmed the in-
creased phosphorylation of Forkhead transcription factors
throughout activated Akt structures, while control structures
exhibited a stochastic pattern confined to matrix-attached
cells (Fig. 1 D, bottom). Hence, the failure of Akt activation
to prevent luminal apoptosis could not be explained by the
lack of phosphorylation of key Akt-mediated survival effec-
tors in the centrally located cells.
 
Cell size and proliferation in activated Akt structures
 
The overall morphological disruption of activated Akt struc-
tures and the persistence of cells in the luminal space despite
apoptosis in the lumen prompted us to examine if the effects
of Akt activation on cell size or cell proliferation contributed
to its phenotype. First, we inspected cell size within Akt-acti-
vated acini by immunostaining with an antibody against
phosphorylated ERM (ezrin/radixin/moesin) proteins (
 

 
P-
ERM). ERM proteins function as linkers of the plasma mem-
brane to the actin cytoskeleton and are located immediately
subjacent to the plasma membrane; hence, we used 
 

 
P-ERM
to outline the plasma membranes in acini and delineate the
size and shape of cells within these structures (Bretscher et al.,
2000; Debnath et al., 2003). Whereas control acini con-
tained cells with a uniform size and a homogeneous cuboidal
shape, cells within activated Akt structures displayed in-
creased size and wide variability in both size and shape (Fig. 2
A). On average, we found a 46% increase in individual cell
size within activated Akt structures; the longest linear dimen-
sion measured 17.4 
 
 
 
6.0 
 

 
m versus 11.9 
 
 
 
2.8 
 

 
m (P 
 

 
0.001 using 
 
t
 
 test) in controls. In some activated Akt struc-
tures, we also observed an increase in size of nuclei of cells;
however, we were unable to detect any changes in DNA con-
tent by FACS
 
®
 
 analysis (Fig. 2 A, bottom right, and not de-
picted). Based on these results, we postulated that the overall
architectural disorganization elicited by Akt activation was at
least partially due to the effects of Akt on the size and shape
of individual cells comprising these structures.
The phase and DAPI-stained morphology of activated Akt
structures indicated that they also contained increased num-
bers of cells (Fig. 1 A and Fig. 2 A). Hence, we further exam-
ined the effects of Akt activation on cell proliferation dur-
Figure 2. Cell size and proliferation in 
activated Akt structures. (A) After 18 d of 3D 
culture, structures grown with or without OHT 
were immunostained with P-ERM (left), to mark 
cell membranes to delineate cell size/shape, 
and DAPI (right). Confocal cross sections through 
the equators of acini are shown. Bars, 25 m. 
(B) Day 6 and 20 acini were immunostained with 
-Ki-67. Representative fields show control and 
OHT-activated Akt structures with occasional 
Ki-67–positive cells at day 20, while HPV E7–
expressing structures continue to proliferate. 
Corresponding phase contrast images are shown 
to the right of each Ki-67 stain. Bars, 50 m. 
(C) Single cell suspensions of the indicated cell 
types were prepared from day 6 and 20 cultures, 
labeled with propidium iodide, and analyzed 
by flow cytometry to quantify the percent of 
cells with DNA content corresponding to the S 
and G2/M (S  G2/M) phases of the cell cycle. 
The mean  SEM of three experiments is shown; 
statistical significance was determined by t test, 
with P  0.05 defined as not significant (NS).
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ing morphogenesis by immunostaining for the proliferation
marker Ki-67 (Scholzen and Gerdes, 2000). Developing
MCF-10A acini exhibit high levels of proliferation during
the first 6 d of 3D culture; thereafter, Ki-67 activity gradu-
ally decreases over the next 10 d. We have previously ob-
served that oncogenes, like cyclin D1, HPV E7, and ErbB2,
allow escape from this proliferative suppression (Muth-
uswamy et al., 2001; Debnath et al., 2002). High levels of
Ki-67 activity were detected during the early stages of mor-
phogenesis in both control and OHT-treated ER-Akt–
expressing acini. In later stage cultures, structures expressing
activated Akt underwent proliferative suppression at a simi-
lar rate to controls; only rare Ki-67–positive cells were de-
tected in day 20 cultures (Fig. 2 B). In contrast, acini ex-
pressing HPV E7 continued to exhibit high levels of Ki-67
activity in late-stage cultures (Fig. 2 B).
To further investigate proliferation during morphogene-
sis, cells from 3D cultures corresponding to the early (day 6)
and late stages (day 20) of acinar development were har-
vested, labeled with propidium iodide, and subject to flow
cytometric analysis in order to quantify the percentage of
cells with a DNA content corresponding to the S and G2/M
(S 
 
 
 
G2/M) phases of the cell cycle (Fig. 2 C). In day 6 cul-
tures of activated Akt cells, we found an approximately two-
fold increase versus controls in the percent of cells in S 
 

 
G2/M. At day 20, Akt-activated cultures exhibited a low
percentage of cells in S 
 
 
 
G2/M that was not significantly
different from controls. In contrast, E7-expressing cells ex-
hibited twofold higher levels of proliferation in both day 6
and day 20 cultures. These results demonstrated that, in
contrast to HPV E7, Akt activation did not allow escape
from regulatory controls that suppress proliferation during
the late stages of morphogenesis in MCF-10A acini (Deb-
nath et al., 2002). Instead, the increased cell number ob-
served in active Akt structures was likely due to enhanced
proliferation during the early stages of morphogenesis.
 
Akt amplifies proliferation in mammary structures 
expressing proliferative oncogenes
 
As Akt did not directly affect proliferative suppression during
normal morphogenesis, we considered the possibility that
Akt activation could enhance proliferation in the context of
other cues, such as those provided by growth factors and
other cancer genes. Thus, we investigated whether Akt could
cooperate with proliferative oncogenes, such as cyclin D1
and HPV E7, in 3D cultures. Stable pools of cells expressing
ER-Akt in combination with cyclin D1 and HPV E7 were
established and cultured in the absence or presence of OHT.
Control acini expressing unactivated ER-Akt along with the
empty vector (LXSN) underwent proliferative arrest (Fig. 3,
top). Without OHT, cyclin D1 or HPV E7 structures ex-
pressing ER-Akt exhibited proliferation in late-stage cultures
(day 20) as previously described for structures expressing cy-
clin D1 or HPV E7 alone (Debnath et al., 2002). Activation
of ER-Akt with OHT in cells expressing cyclin D1 or HPV
E7 gave rise to structures that were on average larger and that
exhibited significantly higher levels of Ki-67 activity than
those treated with ethanol control (Fig. 3, bottom).
As previously reported, we detected increased numbers of
Ki-67–positive cells with HPV E7 as compared with cyclin
D1 in the control cultures (Fig. 3) (Debnath et al., 2002).
Interestingly, this difference in Ki-67 activity between these
Figure 3. Akt activation amplifies 
proliferation in mammary structures 
coexpressing cyclin D1 and HPV E7. 
MCF-10A cells coexpressing ER-Akt with 
LXSN (vector, left), cyclin D1 (middle), 
or HPV E7 (right) were cultured on EHS 
for 20 d with ethanol control (top) or 
1 M OHT (bottom). Representative 
images of -Ki-67–immunostained 
structures along with corresponding 
phase images are shown. Similar results 
were obtained with pBABE as the vector 
control (not depicted). Bars, 50 m.
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two oncoproteins was also evident upon OHT-induced acti-
vation of ER-Akt; the HPV E7–expressing, Akt-activated
structures displayed exceedingly high levels of proliferation
compared with all other conditions (Fig. 3). Based on these
results, we surmised that Akt could amplify the proliferative
events initiated by another stimulus, such as overexpression
of oncoproteins like cyclin D1 or HPV E7.
 
Activated Akt cooperates with proliferative oncogenes 
to promote proliferation and morphogenesis in the 
absence of exogenously added growth factors
 
We further examined the effects of Akt on proliferation by
analyzing its ability to promote proliferation and morpho-
genesis in the absence of added growth factors. Proliferation
of MCF-10A cells in monolayers and in 3D cultures is abso-
lutely dependent on exogenously added EGF and insulin
(Soule et al., 1990; Muthuswamy et al., 2001). We found
that activation of Akt or ectopic expression of cyclin D1 or
HPV E7 were insufficient to allow EGF-independent prolif-
eration in Matrigel cultures (Fig. 4, A and B). Only small
cell clusters, comprised of three to five cells each, developed
over a 25-d period in MCF-10A cultures expressing acti-
vated ER-Akt, cyclin D1, or HPV E7 alone, or in vehicle-
treated cultures coexpressing the proliferative oncogenes
with ER-Akt. (Fig. 4, A and B).
In contrast, when ER-Akt was activated with OHT in cy-
clin D1–expressing cells, small acinar structures (comprised
of 25–30 cells each) developed in the absence of EGF (Fig. 4
A). More strikingly, cells expressing HPV E7 plus active Akt
exhibited robust proliferation and morphogenesis during the
EGF-independent 3D culture; in these assays, large struc-
tures closely resembling those grown in the presence of EGF
developed over a 20-d period (Fig. 4 A). Enumeration of
cells from these assays revealed a 24-fold increase in the
number of cells in cultures of E7 
 
 
 
active Akt cells com-
pared with those expressing E7 alone or those with E7 and
unactivated ER-Akt. Moreover, cells with E7 
 
 
 
active Akt
were able to proliferate and undergo morphogenesis when
Figure 4. Akt and HPV E7 cooperate to 
promote proliferation and morphogenesis 
in the absence of exogenously provided 
growth factors. (A) The indicated cell 
types were cultured in 3D without EGF 
along with ethanol control (left) or 1 M 
OHT (right) for the indicated number of 
days; representative phase-contrast images 
illustrate the development of acinar 
structures in MCF-10A cells coexpressing 
cyclin D1 or HPV E7 where ER-Akt has 
been activated with OHT. Bars, 50 m. 
(B) The indicated cell types were cultured 
in 3D without EGF (or without both EGF 
and insulin) for 25 d, and cell numbers 
were quantified. Results represent the 
mean  SD from three to five indepen-
dent experiments.
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both EGF and insulin were removed from 3D culture (Fig.
4 B). Finally, cells coexpressing HPV E7 and Bcl-2 only
formed small clusters in the absence of EGF, indicating that
inhibiting apoptosis in E7-containing cells does not mimic
the cooperative effect of active Akt and E7 on EGF-inde-
pendent proliferation and morphogenesis. Altogether,
these results indicate that activation of Akt cooperates with
proliferative oncogenes to promote both proliferation and
morphogenesis in the absence of added growth factors.
We subsequently examined whether the ability of HPV
E7 
 
 
 
active Akt cells to proliferate without EGF was due to
the production of a secreted mitogenic factor. Control or
HPV E7–expressing MCF-10A cells (labeled with Cell-
tracker Orange™) were cocultured with MCF-10A cells ex-
pressing HPV E7 
 

 
 active Akt (labeled with GFP). Neither
uninfected nor HPV E7–expressing MCF10A cells prolif-
erated when cocultured with HPV E7 
 
 
 
active Akt cells
(Fig. S2 A, available at http://www.jcb.org/cgi/content/
full/jcb.200304159/DC1, and not depicted). Moreover, in
monolayer culture, conditioned media produced from HPV
E7 
 
 
 
active Akt cells did not support the proliferation of
wild-type MCF-10A cells in the absence of EGF (Fig. S2 B).
As a positive control, we generated cells overexpressing a
constitutively active variant of the upstream MAPK regula-
tor MEK2 (MEK2 DD); activation of the Erk MAPK path-
way via overexpression of Raf can stimulate the production
of several secreted factors (TGF-
 
 
 
and HB-EGF) in MCF-
10A cells (Schulze et al., 2001). Accordingly, MEK2 DD
cells were able to promote the morphogenesis of both unin-
fected MCF-10A and E7 target cells in 3D culture; also,
conditioned media produced from MEK2 DD cells en-
hanced the EGF-independent proliferation of MCF-10A
monolayer cells (Fig. S2, A and B, and not depicted). Thus,
while constitutive activation of the Erk MAPK pathway re-
sults in the production of secreted growth factors, the effect
of Akt activation on growth factor–independent prolifera-
tion and morphogenesis involves cell-autonomous mecha-
nisms. Finally, Akt activation was not able to enhance
anchorage-independent growth in soft agar, either when ex-
pressed alone or in combination with HPV E7, indicating
Figure 5. Rapamycin prevents Akt-medi-
ated disruption of glandular morphology. 
(A) ER-Akt cells were cultured on Matrigel 
for 6 d in the presence of ethanol control 
(top) or 1 M OHT; immunostained with 
-P-Akt Ser473 (green, left) or -P-mTOR 
(green, center and right). Shown are 
DAPI-stained equatorial cross sections. 
Bars, 25 m. (B) Phase morphology of 
day 20 ER-Akt–expressing structures 
cultured with ethanol control (top) or 
1 M OHT (bottom) along with the 
indicated doses of rapamycin. Bars, 50 m. 
(C) Day 12 ER-Akt structures treated with 
ethanol control or 1 M OHT, as well as 
the indicated doses of rapamycin, were 
immunostained with -activated caspase 
3 (green) and -laminin 5 (red). Represen-
tative DAPI-stained equatorial confocal 
cross sections are shown. Bars, 25 m. 
(D) Day 20 ER-Akt structures were grown 
as indicated in the presence of ethanol 
(control), 1M OHT, 20 nM rapamycin, 
or both and immunostained with -P-ERM 
to outline cell membranes and illustrate the 
size and shape of individual cells within 
these structures. Bar, 25 m. (E) ER-Akt 
cells grown as monolayers were treated 
with OHT (1 M), rapamycin (20 nM), 
or both for 6 h, lysed, immunoblotted 
with -P-Akt Ser473 and -P-p70S6K Thr389, 
stripped, and reprobed with -Akt and 
-S6K. (F) ER-Akt structures grown on EHS 
for the indicated days in vehicle control, 
1 M OHT, or 1 M OHT  20 nM 
rapamycin (Rap) were immunostained 
with -P-Akt Ser473; shown are DAPI-
stained equatorial confocal cross sections. 
Bars, 25 m.
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that Akt did not enhance cellular transformation in MCF-
10A cells (Fig. S2 C).
mTOR inhibition with rapamycin prevents Akt-mediated 
disruption of glandular morphology
The combined effects of activated Akt on cell size and prolif-
eration during 3D acinar morphogenesis focused our atten-
tion on the role of pathways regulated by mTOR in mediat-
ing the phenotype elicited by Akt. Activation of mTOR, and
its downstream targets S6K1 (p70S6K) and 4EBP1, has
been shown to positively regulate cell size and proliferation
in mammalian cells (Wiederrecht et al., 1995; Abraham and
Wiederrecht, 1996; Fingar et al., 2002). Abundant evidence
has recently indicated that Akt can regulate mTOR func-
tion; specifically, the phosphorylation of TSC2 (tuberin) by
Akt relieves the inhibitory function of TSC2 on mTOR
and, hence, activates downstream signaling (Manning et al.,
2002; McManus and Alessi, 2002; Potter et al., 2002; Tee
et al., 2002). Accordingly, high levels of phosphorylated
mTOR were detected throughout structures in which ER-
Akt was activated by OHT; in contrast, control acini exhib-
ited the characteristic stochastic phosphorylation pattern
seen with phospho-Akt and phosphorylated Akt substrates
(Fig. 5 A) (Debnath et al., 2002). In corroboration, activa-
tion of ER-Akt monolayer cells with OHT elicited the phos-
phorylation of the mTOR regulator TSC2 as well as the
downstream mTOR effector p70S6K; however, the phos-
phospecific antibodies directed toward these molecules were
not suitable reagents for the interrogation of 3D cultures
(Fig. S1 C and Fig. 5 E).
The macrolide antibiotic rapamycin selectively binds
FKBP12 and acts as a highly specific pharmacological inhib-
itor of mTOR function (Abraham and Wiederrecht, 1996).
To elucidate if mTOR is functionally required for the phe-
notype elicited by Akt, we cultured ER-Akt–expressing cells
on basement membrane with OHT along with varying
doses of rapamycin, ranging from 1 to 50 nM. At concentra-
tions of 5 nM or higher, rapamycin was able to strongly in-
hibit the development of large, distorted structures observed
with Akt activation in 3D culture (Fig. 5 B). In the presence
of rapamycin, activated Akt structures exhibited typical
MCF-10A acinar morphology with normal levels of luminal
apoptosis (Fig. 5 C). Individual cells within these structures
displayed a uniform normal size and cuboidal shape that
Figure 6. Rapamycin precludes the cooperative 
effects of Akt on oncogene-driven, EGF-
independent proliferation. (A) Cells coexpressing 
ER-Akt along with LXSN (top) or HPV E7 (bottom) 
were 3D cultured for 20 d in the absence of 
EGF but with the indicated drug treatments; 
representative phase-contrast images are shown. 
Bar, 50 m. (B) Cells coexpressing ER-Akt with 
LXSN or HPV E7 were cultured in 3D for 20 d 
without EGF but with the indicated drug 
treatments; thereafter, cell numbers were 
quantified. Results represent the mean  SD 
from three independent experiments.
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phenotypically resembled controls (Fig. 5 D). Furthermore,
rapamycin did not adversely affect proliferation or morpho-
genesis in both uninfected MCF-10A acini and ER-Akt con-
trol structures (Fig. 5, B–D, and not depicted). Thus, only
activated Akt structures were highly susceptible to the in-
hibitory effects of rapamycin on mTOR function. More-
over, rapamycin treatment inhibited the phosphorylation of
p70S6K, but not Akt or ER-Akt, in OHT-treated mono-
layer cultures (Fig. 5 E). Also, throughout morphogenesis,
ER-Akt structures grown in the presence of both OHT and
rapamycin displayed high levels of phosphorylated Akt that
were comparable to structures cultured in OHT alone (Fig.
5 F). Overall, these results indicate that mTOR signaling
pathways are required for the phenotypic effects mediated
by Akt activation during morphogenesis.
Rapamycin inhibits the cooperative effect of Akt 
on oncogene-driven growth factor–independent 
proliferation and morphogenesis
As the cooperative influence of Akt activation on HPV E7–
driven proliferation in the absence of EGF appeared to in-
volve a cell-autonomous mechanism, we also examined the
requirement for mTOR function for this phenotype. Both
LXSN  ER-Akt– and HPV E7  ER-Akt–expressing cells
were cultured in Matrigel without EGF, in the presence of
OHT, along with varying doses of rapamycin. Rapamycin
was able to markedly inhibit EGF-independent morpho-
genesis of cells with E7  activated Akt at both the 5 and
20 nM doses; only small clusters developed in these cul-
tures, similar to E7  ER-Akt controls (Fig. 6 A). Quantifi-
cation of cell numbers corroborated near complete inhi-
bition of proliferation by HPV E7  active Akt with
rapamycin (Fig. 6 B). Thus, mTOR function is required for
the cooperative effect of Akt activation on oncogene-driven
proliferation by HPV E7.
Discussion
Activation of Akt in tumor cells enhances tumor cell growth
and results in the phosphorylation of numerous substrates,
which are believed to positively impact on three major bio-
logical processes relevant to cancer progression: cell prolifer-
ation (increased cell number), cell growth (increased cell
size), and survival (Vivanco and Sawyers, 2002). We have
employed the in vitro 3D culture of mammary epithelial
cells to explore three principal issues concerning the effect of
Akt activation in epithelial cells. First, we have examined
how the influence of Akt activation on the aforementioned
processes in individual cells impacts on the higher order ar-
chitecture of polarized epithelial structures. Second, we have
attempted to elucidate how these individual cellular pro-
cesses contribute to the phenotype produced by Akt in both
normal and oncogene-expressing structures. Finally, we
have investigated the role of mTOR in mediating the Akt-
induced effects on acinar architecture.
Most importantly, we have observed that Akt activation
enhances proliferation stimulated by growth factors during
early morphogenesis, although it is not sufficient to over-
come signals causing proliferative arrest, thus limiting the
proliferative potential of Akt in 3D structures. Hence, the
proliferative signals modulated by Akt are fundamentally
distinct from those induced by activated ErbB2, cyclin D1,
or HPVE7, which are all able to escape proliferative suppres-
sion during morphogenesis (Debnath et al., 2002). The pro-
liferative suppression we have observed in activated Akt
structures is consistent with the noticeable absence of hyper-
plastic lesions in the mammary gland of transgenic mice ex-
pressing activated variants of Akt (Hutchinson et al., 2001;
Schwertfeger et al., 2001). Moreover, we provide evidence
that the proliferative influences of Akt on epithelial cells are
primarily cooperative in nature. Indeed, activated Akt signif-
icantly amplifies the proliferation provoked by cyclin D1 or
HPV E7 during morphogenesis. Moreover, while cyclin D1
and HPV E7 are able to promote constitutive proliferation
in MCF-10A acini, this activity is nonetheless EGF driven;
remarkably, activated Akt can cooperate with these oncopro-
teins to promote EGF-independent proliferation and mor-
phogenesis. Akt has been implicated in direct control of cell
cycle progression by several mechanisms, including direct
phosphorylation-mediated changes in protein stability and
subcellular localization of cell cycle inhibitors, p21cip/waf and
p27kip, and the accumulation of cyclin D1 via phosphoryla-
tion-mediated inactivation of glycogen synthase kinase 3
pathway (Diehl et al., 1998; Zhou et al., 2001; Liang et al.,
2002; Shin et al., 2002; Viglietto et al., 2002). However, we
have been unable to detect changes in the protein levels or
subcellular location of any of these proteins upon ER-Akt
activation in MCF-10A cells (unpublished data). Rather,
our results reveal that mTOR function is required for the
cooperative effect of Akt on proliferation, as rapamycin sup-
presses Akt-induced hyperproliferation.
Our studies also indicate that the effect of Akt on individ-
ual cell size and shape may contribute to aberrations in the
higher order architecture of epithelial structures. The large
distorted structures resulting from Akt activation contain in-
dividual cells with increased cell size and a wide variability in
cell size and shape. This lack of uniformity among individ-
ual cells, the “building blocks” that make up an epithelial
acinus, may hinder the assembly of a proper glandular struc-
ture. Aberrations in glandular architecture commonly ob-
served in both premalignant and invasive epithelial cancers
are notable for both increased cell size and variability in in-
dividual cell size and shape; the potential contribution of
the PI3K/Akt and mTOR pathways to these histological
changes in vivo remains unknown. Notably, our results are
similar to those observed upon transgenic overexpression of
activated Akt in the mouse prostate, which exhibit hyper-
plastic, disorganized glands resembling human prostatic in-
traepithelial neoplasia (Majumder et al., 2003).
Akt-mediated disruption of epithelial cell polarity may
also contribute to the morphological changes in acini; how-
ever, we have been unable to detect changes in the distribu-
tion of several polarity markers in MCF-10A structures.
Moreover, we have not observed any alterations in the sub-
cellular location of known polarity regulators (e.g., Discs
Large) or in the location of tight junction proteins (e.g.,
ZO-1) upon activating ER-Akt in Madin-Darby canine kid-
ney 2 polarized monolayers, a commonly used assay for epi-
thelial cell polarity (Knust and Bossinger, 2002; unpub-
lished data). In Drosophila, perturbations in Akt expression
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affect cell size, which influences the overall compartment
size in the imaginal disc (Verdu et al., 1999). Likewise, mu-
tations in Drosophila PI3K and TOR pathway components
often produce cell size phenotypes, which ultimately impact
on organ size or body size (Edgar, 1999). Similarly, trans-
genic overexpression of activated Akt in the mouse heart re-
sults in increased individual size and heart size (Shioi et al.,
2002). However, in contrast to our results, the overall archi-
tecture of the affected tissues and organs in all of these cases
appears intact. The architectural distortion and variability in
cell size and shape we have observed could be secondary to
local differences in Akt activation within the cells making up
these structures. Importantly, the conditionally active Akt
variant we have used is subject to regulation by PI3K ac-
tivity, as treatment of ER-Akt with the PI3K inhibitor
Ly294002 significantly reduces its activity. Also, in prelimi-
nary studies to monitor PI3K activation using a GFP re-
porter fused to the pleckstrin homology domain of Akt, we
have found a stochastic pattern of PI3K activation within
acini resembling that of Akt activation (Hall, A.B., personal
communication; unpublished data). Hence, stochastic dif-
ferences in PI3K activity among individual cells could mod-
ulate the activation of ER-Akt and contribute to the variable
size and shape changes within cells.
Surprisingly, we have observed that the protection from
luminal apoptosis provided by Akt is significantly weaker
than the activation of ErbB2 or the overexpression of the
antiapoptotic proteins Bcl-2 and Bcl-XL (Debnath et al.,
2002). Nevertheless, several lines of evidence do support a
role for Akt in regulating cell survival in mammary epithe-
lium. First, we consistently have detected viable cells within
the lumens of activated Akt structures, suggesting that acti-
vation of Akt may provide some prosurvival activity. Sec-
ond, we cannot exclude that local signaling differences
within the centrally located cells may regulate the prosur-
vival activity of Akt in the lumen; although we have clearly
demonstrated the increased phosphorylation of Forkhead
transcription factors in centrally located cells, the spatial pat-
tern of activation is still stochastic. Hence, individual cells
exhibiting reduced levels of Akt activation or Forkhead
phosphorylation could still remain susceptible to luminal
apoptosis. Finally, in MCF-10A and other epithelial cells,
Akt provides significant protection from apoptosis upon de-
tachment from matrix, commonly termed anoikis (Frisch
and Francis, 1994; Khwaja et al., 1997; Reginato et al.,
2003). Further experiments are needed to clarify the mecha-
nistic basis for the luminal apoptosis that we have observed
in activated Akt structures.
Finally, we have found that effects of Akt activation on
morphological disruption, proliferation, and cell size and
shape are all prevented by rapamycin, a highly specific phar-
macological inhibitor of mTOR (Abraham and Wieder-
recht, 1996). These results argue that mTOR function is
critically required for Akt-mediated phenotypic changes in
mammary epithelial structures. Although the precise bio-
chemical relationship between the PI3K/Akt and mTOR
signaling pathways remains a subject of intense investiga-
tion, recent studies have revealed that Akt can regulate
mTOR function by phosphorylating TSC2 (tuberin). This
Akt-induced phosphorylation relieves the inhibitory func-
tion of TSC2 on mTOR and, hence, activates downstream
signaling components (Manning et al., 2002; Potter et al.,
2002; Tee et al., 2002). Our results further indicate that the
mTOR pathway regulates the effects of Akt activation on
both cell size and proliferation. mTOR is believed to regu-
late cell biosynthesis, growth, and proliferation via its ef-
fects on protein translation; modulation of mTOR, and
its downstream targets S6K1 and 4EBP1/eIF4E, has been
shown to positively regulate both cell size and proliferation
in response to both nutrient availability and mitogenic sig-
nals (Scott et al., 1998; Sekulic et al., 2000; Rohde et al.,
2001; Fingar et al., 2002). Also, recent studies in lympho-
cytes indicate that the effects of Akt on both cell size and
surface expression of nutrient transporters are mTOR de-
pendent (Edinger and Thompson, 2002). How down-
stream effectors of the mTOR pathway modulate Akt-
directed changes during morphogenesis is an important
area for further study.
Rapamycin analogues, such as CCI-779, have emerged as
potentially important chemotherapeutic agents in cancers
because of their high specificity and low systemic toxicity
(Abraham, 2002). Rapamycin treatment inhibits focus for-
mation in chicken fibroblasts expressing myristoylated, acti-
vated versions of PI3K and Akt; moreover, PTEN-deficient
tumor cells display an enhanced sensitivity to CCI-779 in
both in vitro and in vivo models (Aoki et al., 2001; Neshat
et al., 2001; Podsypanina et al., 2001). Our results corrobo-
rate these previous studies and support the further evalua-
tion of rapamycin analogues as chemotherapeutic agents in
tumors where the PI3K/Akt pathway has been activated.
Moreover, several experimental approaches in this report
may serve as tractable biological assays for interrogating Akt
functional activity within polarized epithelial structures, and
hence, may be useful for the initial in vitro evaluation of new
pharmacological agents targeting various components of the
PI3K/Akt and mTOR signaling pathways.
Materials and methods
Materials
See supplemental Materials and methods (available at http://www.jcb.org/
cgi/content/full/jcb.200304159/DC1) for the sources of cultured cells,
chemicals, and antibodies.
Retroviral vectors and virus production
The ER-Akt–expressing retroviral vector, pWZLmyrAkt-HA-ER, was a gen-
erous gift from R. Roth (Stanford University, Stanford, CA). pBABEpuro cy-
clin D1 was constructed from pFLEX cyclin D1 (a gift from A. Diehl, Uni-
versity of Pennsylvania, Philadelphia, PA). pBabepuroMEK2-DD was
provided by S. Meloche (University of Montreal, Montreal, Canada). VSV-
pseudotyped retroviruses were produced as previously described (Ory et
al., 1996). Retroviral vectors encoding HPV 16 E7 and the empty vector
(LXSN) were produced from the cell lines PA317-16E7 and PA317-LXSN,
respectively, obtained as a gift from D. Galloway (Fred Hutchinson Cancer
Research Center, Seattle, WA).
Generation of MCF-10A cell lines
MCF-10A cells (4 	 105 cells) infected with the retroviruses above and sta-
ble populations were obtained by selection with 2 g/ml puromycin
(Sigma-Aldrich) or 200 g/ml G418 (Sigma-Aldrich). Stable pools of MCF-
10A cells that coexpressed HPV16 E7 and ER-Akt were generated by seri-
ally infecting with HPV16 E7 retrovirus, followed by pWZLmyrAkt-HA-ER;
stable pools coexpressing cyclin D1 with ER-Akt were obtained by serial
infection of pBABEpuro cyclin D1 followed by pWZLmyrAkt-HA-ER. Pro-
tein expression was confirmed by immunoblotting.
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Morphogenesis assays
The 3D culture of MCF-10A cells was performed as previously described
(Debnath et al., 2003). OHT (1 mM stock) and rapamycin (20 M stock)
were dissolved in ethanol. For ER-Akt activation with OHT, the assay me-
dia (DMEM/F12 supplemented with 2% donor horse serum; 5 ng/ml EGF;
10 g/ml insulin; 100 ng/ml cholera toxin; 0.5 g/ml hydrocortisone, anti-
biotics, and 2% Matrigel) was replaced with 1 M OHT-containing assay
media (or ethanol control) starting on day 2 or day 3 of 3D culture and
refed every 4 d thereafter. Where indicated, rapamycin was added to cul-
tures at the reported dose on day 2 or 3 of 3D culture and replaced every
4 d thereafter. In 3D morphogenesis assays performed without EGF, or
without both EGF and insulin, these reagents were removed as indicated
from the assay media described above.
Immunofluorescence analysis and image acquisition
The immunostaining of acinar structures was performed as previously de-
scribed (Debnath et al., 2003). Indirect immunofluorescent and phase im-
aging were performed on a Nikon TE300 microscope equipped with a
mercury lamp and CCD camera. Confocal analyses were performed using
the Carl Zeiss MicroImaging, Inc. LSM410 confocal microscopy system
with LSM version 3.99. The images presented represent four or more inde-
pendent experiments. All images were converted to TIFF format and ar-
ranged using Adobe Photoshop 7.0®.
Analysis of cell number and DNA content
To enumerate cell numbers from morphogenesis assays, cultures were
treated with 0.5% trypsin, 5 mM EDTA for 30–40 min at 37
C. The trypsin-
treated structures were then triturated to generate single cell suspensions,
washed, and resuspended in a fixed volume of PBS, and cells were
counted using a Beckman Coulter counter or hemacytometer. For flow cy-
tometric analysis of DNA content, single cell suspensions (from 10,000
acini) were prepared as above, fixed in 80% ethanol at 4
C, washed with
FACS® buffer (PBS plus 1% FBS), incubated for 30 min at 37
C with 10 g/
ml propidium iodide, 250 g/ml RNAase A in FACS® buffer, and analyzed
on a FACSCalibur® (BD Biosciences) flow cytometer.
Online supplemental material
The supplemental material (Figs. S1 and S2 and supplemental Materi-
als and methods) is available at http://www.jcb.org/cgi/content/full/
jcb.200304159/DC1. The data presented in each supplemental figure are
described within the text and online legends. Additional experimental de-
tails are provided in the supplemental Materials and methods.
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